Abaloparatide
Complete Research Guide
Open each section for the available evidence. Gaps are stated rather than inferred.
Overview
Abaloparatide is listed as bone / pthrp analog.
- •Postmenopausal Osteoporosis
Regulatory status: FDA-Approved Rx.
Structure & Properties
Compound: Abaloparatide; also known as Tymlos.
Pharmacologic class: Bone / PTHrP Analog.
Known delivery routes: Subcutaneous.
Sequence, molecular weight, salt form, and excipient details are formulation-specific and are not listed unless verified by a manufacturer or laboratory COA.
How It Works
PTHrP(1-34) analog — selective PTH1R signaling favoring bone formation over resorption; faster BMD gain than teriparatide.
- •Greater BMD gains vs teriparatide
- •Vertebral and non-vertebral fracture reduction
- •Daily autoinjector
Human Research
Evidence grade: Clinical RCT (Phase III)
Clinical RCT (Phase III). Phase III ACTIVE trial.
Laboratory Research
Phase III ACTIVE trial
Preclinical findings describe biological plausibility, not proven benefit in people. Animal and laboratory doses do not translate directly to human use.
Processing & Interactions
Timing and exposure
Once daily SubQ, same time each day. Sit/lie for first doses.
Potential interactions and combinations to avoid
- •Teriparatide, Romosozumab overlap
- •Hypercalcemia
Absorption, half-life, metabolism, and clearance can vary by formulation and route. Use prescribing information when an approved product exists.
Safety & Precautions
Known or reported risks
- •Osteosarcoma (class warning)
- •Hypercalcemia
- •Dizziness
- •Palpitations
Contraindications
- •Prior skeletal radiation
- •Bone metastases
- •Pediatric
- •Hypercalcemia, hyperparathyroidism, or Paget's disease of bone
- •History of skeletal radiation therapy or osteosarcoma
- •Unexplained elevated alkaline phosphatase or bone metastases
- •Myocardial infarction or stroke within the previous 12 months (sclerostin inhibitors)
- •Severe renal impairment or active kidney stone disease
- •Bleeding disorders or anticoagulant therapy without physician guidance (injection-site haematoma)
- •Active skin infection, cellulitis, or lipohypertrophy at intended injection sites
- •Inability to maintain sterile technique or safe sharps disposal
- •Cumulative lifetime exposure beyond approved treatment duration
- •Known hypersensitivity or prior reaction to this compound or any excipient/diluent
- •Pregnancy, attempting conception, or breastfeeding unless prescribed and monitored by a physician
- •Children and adolescents with open growth plates (unless under specialist endocrine care)
- •Active or recently treated malignancy without oncology clearance
- •Use without a confirmed diagnosis, baseline labs, and licensed clinical supervision
Unknown long-term toxicity should be assumed where controlled human data are limited. Seek urgent care for a severe or unexpected reaction.
Administration & Studied Formulations
Reference range: 80 mcg/day
Frequency: Daily
Cycling: Max 2-year lifetime use.
Subcutaneous (SubQ)
Default route for most research and therapeutic peptides — best absorption for reconstituted powder.
31G × 5/16" insulin syringe (U-100). 100 units = 1 mL. Pinch skin at abdomen (2" from navel), outer thigh, or love handle. Insert at 45–90°. Rotate sites daily to prevent lipohypertrophy. Alcohol-swab site, air-dry, inject slow, hold 5 sec.
Dosing information is educational context, not a personal recommendation. Approved products must follow their label and prescriber instructions.
Applications & Related Therapies
Potentially complementary measures
- •Followed by bisphosphonate for maintenance
Clinical use should account for diagnosis, approved alternatives, nutrition, activity, sleep, rehabilitation, current medicines, and appropriate monitoring.
Cases, Considerations & Ethics
Decision framework: establish the clinical goal, confirm evidence quality and legal status, screen contraindications and interactions, compare approved alternatives, define monitoring and stopping criteria, and use shared decision-making with a licensed clinician.
Case evidence: individual reports cannot establish safety or effectiveness and should not outweigh controlled trials.
Ethics: informed consent should distinguish established care from experimental use, disclose uncertainty and cost, avoid overstated claims, and never substitute research products for medically necessary care.
Function
Dosing
Recommended Time of Day
Same time each day — morning is typical.
See “Timing & Interactions” below for full fasted/fed circumstances, what to avoid combining, and what pairs well.
Administration & Technique
Injection & Application Sites
- Abdomen — 2 in (5 cm) away from the navel, either side. Fastest, most consistent SubQ absorption.
- Flank / love handle — Lateral fat pad above the hip. Good rotation site when the abdomen is tender.
- Outer thigh — Upper outer quadrant, a hand-width below the hip. SubQ pinch at 45°.
Diagram is a general illustration, not a medical instruction. Rotate sites every injection, keep 1 in (2.5 cm) between recent sites, and avoid scars, moles, bruises and the navel area.
Cycling
Max 2-year lifetime use.
Timing & Interactions
- ·Teriparatide, Romosozumab overlap
- ·Hypercalcemia
- ·Followed by bisphosphonate for maintenance
Storage & Reconstitution
Reconstitution Calculator
1 mL = 100 units on a standard U-100 insulin syringe. Draw to the nearest 0.5 unit and confirm dosing with a clinician before injection.
Your Notes
Sign in to save personal notes on Abaloparatide and sync them to Vial Lab.
Benefits
- ·Greater BMD gains vs teriparatide
- ·Vertebral and non-vertebral fracture reduction
- ·Daily autoinjector
Risks
- ·Osteosarcoma (class warning)
- ·Hypercalcemia
- ·Dizziness
- ·Palpitations
Contraindications
- ·Prior skeletal radiation
- ·Bone metastases
- ·Pediatric
- ·Hypercalcemia, hyperparathyroidism, or Paget's disease of bone
- ·History of skeletal radiation therapy or osteosarcoma
- ·Unexplained elevated alkaline phosphatase or bone metastases
- ·Myocardial infarction or stroke within the previous 12 months (sclerostin inhibitors)
- ·Severe renal impairment or active kidney stone disease
- ·Bleeding disorders or anticoagulant therapy without physician guidance (injection-site haematoma)
- ·Active skin infection, cellulitis, or lipohypertrophy at intended injection sites
- ·Inability to maintain sterile technique or safe sharps disposal
- ·Cumulative lifetime exposure beyond approved treatment duration
- ·Known hypersensitivity or prior reaction to this compound or any excipient/diluent
- ·Pregnancy, attempting conception, or breastfeeding unless prescribed and monitored by a physician
- ·Children and adolescents with open growth plates (unless under specialist endocrine care)
- ·Active or recently treated malignancy without oncology clearance
- ·Use without a confirmed diagnosis, baseline labs, and licensed clinical supervision
Regulatory
FDA-Approved Rx
Veterinary Use (Pets)
No established veterinary protocol for Abaloparatide. Consult a licensed veterinarian before considering off-label use in any species.
Full veterinary reference →Functional Groups
Cited Works
Tap any study to open the published work.